Second-line therapy in diffuse large B-cell lymphoma (DLBCL): treatment patterns and outcomes in older patients receiving outpatient chemotherapy

References

• Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 17 Regs Research Data, Nov 2010 Sub (2000-2008), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; 2011 Apr [cited 2011 Nov 5].
   Google Scholar
• Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2010 Sub (1973-2008), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; 2011 Apr [cited 2011 Nov 5].
   Google Scholar
• Zelenetz AD. Guidelines for NHL: updates to the management of diffuse large B-cell lymphoma and new guidelines for primary cutaneous CD30+ T-cell lymphoproliferative disorders and T-cell large granular lymphocytic leukemia. JNCCN. 2014;12:797–800.
   Web of Science ®Google Scholar
• Ghielmini M, Vitolo U, Kimby E, et al. ESMO guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Ann Oncol. 2013;24:561–576.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller E, Morrison V, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–3127.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, et al. CHOP Chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–242.
   Google Scholar
• Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116:2040–2045.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–391.
   PubMed Web of Science ®Google Scholar
• Williams JN, Rai A, Lipscomb J, et al. Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma. Cancer. 2015;121:1800–1808.
   PubMed Web of Science ®Google Scholar
• Griffiths RI, Gleeson ML, Mikhael J, et al. Comparative effectiveness and cost of adding rituximab to first-line chemotherapy for elderly patients diagnosed with diffuse large B-cell lymphoma. Cancer. 2012;118:6079–6088.
   PubMed Web of Science ®Google Scholar
• Griffiths R, Gleeson M, Knopf K, et al. Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL). BMC Cancer. 2010;10:625. doi: 10.1186/1471-2407-10-625.
   PubMed Web of Science ®Google Scholar
• Colosia A, Njue A, Trask PC, et al. Clinical efficacy and safety in relapsed/refractory diffuse large B-cell lymphoma: a systematic literature review. Clin Lymphoma Myeloma Leuk. 2014;14:343–355.e6.
   PubMed Web of Science ®Google Scholar
• Hamlin PA, Satram-Hoang S, Reyes C, et al. Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results - medicare analysis. Oncologist. 2014;19:1249–1257.
   PubMed Web of Science ®Google Scholar
• Böll B, Goergen H, Arndt N, et al. Relapsed Hodgkin lymphoma in older patients: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol. 2013;31:4431–4437.
   PubMed Web of Science ®Google Scholar
• Warren JL, Klabunde CN, Schrag D, et al. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40:IV–3–18.
   Google Scholar
• Project. TIN-HLPFA predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med. 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Davidoff AJ, Tang M, Seal B, et al. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28:2191–2197.
   PubMed Web of Science ®Google Scholar
• Klabunde CN, Warren JL, Legler JM. Assessing comorbidity using claims data: an overview. Med Care. 2002;40:IV–35–36.
   Web of Science ®Google Scholar
• Klabunde CN, Legler JM, Warren JL, et al. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007;17:584–590.
   PubMed Web of Science ®Google Scholar
• Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40:IV–55–61.
   Web of Science ®Google Scholar
• Royston P, Parmar MKB. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modeling and estimation of treatment effects. Stat Med. 2002;21:2175–2197.
   PubMed Web of Science ®Google Scholar
• Lambert PC, Royston P. Further development of flexible parametric models for survival analysis. Stata J. 2009;9:265–290.
   Web of Science ®Google Scholar
• Griffiths RI, Gleeson ML, Danese MD, et al. Inverse probability weighted least squares regression in the analysis of time-censored cost data: an evaluation of the approach using SEER-Medicare. Value Health. 2012;15:656–663.
   PubMed Web of Science ®Google Scholar
• Lin DY. Linear regression analysis of censored medical costs. Biostatistics. 2000;1:35–47.
   PubMedGoogle Scholar
• Lowry L, Smith P, Cunningham D, et al. Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapy. J Geriatr Oncol. 2013;4:134–140.
   PubMed Web of Science ®Google Scholar
• Redondo AM, Pomares H, Vidal MJ, et al. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study. Br J Haematol. 2014;164:668–674.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184–4190.
   PubMed Web of Science ®Google Scholar
• Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:498–505.
   PubMed Web of Science ®Google Scholar
• Sehn LH. A decade of R-CHOP. Blood. 2010;116:2000–2001.
   PubMed Web of Science ®Google Scholar
• Andrade SE, Kahler KH, Frech F, et al. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf. 2006;15:565–574; discussion 575–577.
   PubMed Web of Science ®Google Scholar
• Müller C, Murawski N, Wiesen MHJ, et al. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012;119:3276–3284.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Müller C, Zeynalova S, et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood. 2014;123:640–646.
   PubMed Web of Science ®Google Scholar
• Tao L, Foran JM, Clarke CA, et al. Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era. Blood. 2014;123:3553–3562.
   PubMed Web of Science ®Google Scholar
• Gerber DE, Rasco DW, Le P, et al. Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy. J Thorac Oncol. 2011;6:365–371.
   PubMed Web of Science ®Google Scholar